Geron's Q2 revenue rises on RYTELO growth
GERN•Outlook
- Company reiterated 2026 RYTELO net product revenue guidance of $220 mln to $240 mln
- Geron expects 2026 total operating expenses of $230 mln to $240 mln
- Company says existing cash and anticipated revenues are sufficient to fund operations for the foreseeable future
Quarterly results and revenue drivers
Geron's Q2 revenue rose on RYTELO growth.
- US biopharmaceutical firm's Q2 product revenue grew 11% quarter-on-quarter and 17% yr/yr
- Company said Q2 results were driven by a third consecutive quarter of demand growth for RYTELO in LR-MDS patients
- Company said ordering accounts for RYTELO increased by roughly 8% in Q2 to about 1,575
- Company attributed increased net loss and operating expenses to non-cash inventory-related expenses
Key financial details and analyst coverage
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Loss Per Share | $0.02 | ||
| Q2 Net Loss | $16.68 mln |
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the biotechnology & medical research peer group is "buy"
